These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

94 related articles for article (PubMed ID: 13957747)

  • 1. Metabolic studies on the effects of sprinolacton.
    JICK H; MORRISON RS; MOORE EW; CHALMERS TC
    Metabolism; 1963 May; 12():381-7. PubMed ID: 13957747
    [No Abstract]   [Full Text] [Related]  

  • 2. [PATHOPHYSIOLOGY AND CLINICAL ASPECTS OF SECONDARY ALDOSTERONISM AND ITS TREATMENT].
    HOFFMEISTER W
    Folia Clin Int (Barc); 1964 Mar; 14():124-44. PubMed ID: 14153959
    [No Abstract]   [Full Text] [Related]  

  • 3. [Inhibition of natriuretic effect of angiotensin by spirolactones and salidiuretics in cirrhosis and arterial hypertension].
    Kuntzmann F; Reville P; Kurtz T; Jahn H; Stahl J
    Pathol Biol (Paris); 1969 May; 17(9):447-58. PubMed ID: 4308377
    [No Abstract]   [Full Text] [Related]  

  • 4. [Some effects of spironolactones on the tubular functions of the kidney in various clinical conditions].
    MIGONE L; AMBROSOLI S; FERIOLI V; MISSALE G; BARONIO G; PRATI S; ANDREUCCI V
    Minerva Med; 1963 Mar; 54():817-23. PubMed ID: 13935692
    [No Abstract]   [Full Text] [Related]  

  • 5. [Diuretics in cirrhosis. Accidents. Indications].
    Andrieu J; Lesueur G
    Presse Med (1893); 1969 Mar; 77(16):575-8. PubMed ID: 5783378
    [No Abstract]   [Full Text] [Related]  

  • 6. Does the amount of edema in patients affect the magnitude of response to a dose of a diuretic acting on the renal tubules?
    Gold H; Messeloff CR; Mehta D; Kwit NT; Golfinos AJ; Zahm WN; Goessel E; Morris A
    J Clin Pharmacol J New Drugs; 1969; 9(6):374-83. PubMed ID: 5260200
    [No Abstract]   [Full Text] [Related]  

  • 7. The physiopathologic basis and limitations of treatment of cirrhotic edema with diuretics retaining potassium.
    Vesin P
    Mater Med Pol; 1974; 6(3):199-201. PubMed ID: 4444335
    [No Abstract]   [Full Text] [Related]  

  • 8. [The treatment of ascitic cirrhosis with aldosterone antagonists (spirolactones). Clinical and metabolic study of 13 cases treated with spironolactone].
    ALBEAUX-FERNET M; CHABOT J; ROMANI JD
    Sem Hop; 1962 Jul 4-10; 38():2207-22. PubMed ID: 13860062
    [No Abstract]   [Full Text] [Related]  

  • 9. [FANCONI'S SYNDROME WITH LIVER CIRRHOSIS IN AN INFANT].
    BECO V; FILIP O; KAMENICKA E
    Cesk Pediatr; 1963 Dec; 18():1085-9. PubMed ID: 14109667
    [No Abstract]   [Full Text] [Related]  

  • 10. The Impact of Spironolactone on the Severity of Portal-Systemic Collaterals and Hepatic Encephalopathy in Cirrhotic Rats.
    Hsu SJ; Wang SS; Huo TI; Lee FY; Huang HC; Chang CC; Hsin IF; Ho HL; Lin HC; Lee SD
    J Pharmacol Exp Ther; 2015 Oct; 355(1):117-24. PubMed ID: 26260462
    [TBL] [Abstract][Full Text] [Related]  

  • 11. [Spironolactone in the treatment of portal hypertension in liver cirrhosis. A new therapeutic principle?].
    Klein CP
    Dtsch Med Wochenschr; 1985 Nov; 110(46):1774-6. PubMed ID: 4054003
    [TBL] [Abstract][Full Text] [Related]  

  • 12. [DIURETIC THERAPY OF THE ASCITIC FORM OF LIVER CIRRHOSIS WITH ANGIOTENSIN II AND THE MECHANISM OF ITS ACTION].
    PAZOUREK M; KUECHEL O; HORKY K
    Sb Lek; 1964 Oct; 66():289-96. PubMed ID: 14199701
    [No Abstract]   [Full Text] [Related]  

  • 13. [ON THE COMBINATION OF SPIRONOLACTONE AND METOPIRONE IN THE TREATMENT OF DECOMPENSATED LIVER CIRRHOSIS].
    BRUNNER E; RISSEL E
    Wien Klin Wochenschr; 1964 Dec; 76():890-3. PubMed ID: 14336956
    [No Abstract]   [Full Text] [Related]  

  • 14. Significance of hypokalaemia due to diuretics.
    Leemhuis MP; Struyvenberg A
    Neth J Med; 1973; 16(1):18-28. PubMed ID: 4572424
    [No Abstract]   [Full Text] [Related]  

  • 15. Attenuation by spironolactone of the magnesiuric effect of acute frusemide administration in patients with liver cirrhosis and ascites.
    Stergiou GS; Mayopoulou-Symvoulidou D; Mountokalakis TD
    Miner Electrolyte Metab; 1993; 19(2):86-90. PubMed ID: 8377729
    [TBL] [Abstract][Full Text] [Related]  

  • 16. [THE MODES OF RENAL ACTION OF ALDOSTERONE INHIBITORS. DEDUCTIONS CONCERNING THE POINTS OF ATTACK OF ALDOSTERONE AT THE LEVEL OF THE KIDNEY].
    ROMANI JD; BERNHEIM R; GOOSENS F
    Ann Endocrinol (Paris); 1963; 24():588-97. PubMed ID: 14051313
    [No Abstract]   [Full Text] [Related]  

  • 17. Spironolactone (Aldactone) therapy for ascites due to cirrhosis of the liver.
    LOCKWOOD CH
    Can Med Assoc J; 1961 Sep; 85(11):631-7. PubMed ID: 13763007
    [No Abstract]   [Full Text] [Related]  

  • 18. [TUBULAR EFFECTS AND RENAL ELIMINATION OF SPIROLACTONES].
    HOLLMANN G; SENFT G; WERNER C
    Naunyn Schmiedebergs Arch Exp Pathol Pharmakol; 1964 Jun; 247():419-28. PubMed ID: 14251007
    [No Abstract]   [Full Text] [Related]  

  • 19. Aldosterone antagonist (spironolactone) as an adjunct in the management of ascites in cirrhosis of the liver.
    TOH CC; KHOO OT
    Singapore Med J; 1962 Dec; 3():182-92. PubMed ID: 13985291
    [No Abstract]   [Full Text] [Related]  

  • 20. [EFFECTS OF DIURETICS ON CARDIAC OUTPUT IN LIVER CIRRHOSIS].
    EVEN P; NICOLLO F; BENHAMOU JP; FAUVERT R
    Bull Mem Soc Med Hop Paris; 1963 Nov; 114():1285-93. PubMed ID: 14098212
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 5.